4 To 5 Amino Acid Residues In Defined Sequence Patents (Class 530/330)
  • Patent number: 10246410
    Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 2, 2019
    Assignee: Life Technologies Corporation
    Inventors: Wenjun Zhou, Kyle Gee, Yolanda Tennico, Peter Slade, Hee Chol Kang, Shaheer Khan, Brian Evans, James Stray
  • Patent number: 10220073
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: March 5, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais
  • Patent number: 10151764
    Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 11, 2018
    Assignee: The Cleveland HeartLab
    Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
  • Patent number: 10144740
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: December 4, 2018
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 10138270
    Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: November 27, 2018
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo
  • Patent number: 10072041
    Abstract: Method for preparing a peptide assembly of n fragments and n?1 amino acids bearing a thiol function, represented by the formula: A1-C1-A2-C2-A3- . . . -Ci?1-Ai- . . . -Cn?1-An??(I) in which A1, A2, A3, . . . Ai . . . , An are peptide fragments, C1, C2, C3 . . . Ci?1 . . . Cn?1 are amino acid residues bearing a thiol function, n is comprised between 3 and 50, and i is 2 to n, in which a peptide-thioester is prepared of formula: A1-SR (II) in which A1 is a peptide fragment and SR is an alkyl thioester residue, R being alkyl optionally substituted, starting from a bis(2-sulphanylethyl)amino peptide.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: September 11, 2018
    Assignees: Centre National de la Recherche Scientifique, Universite de Lille 1 Sciences et Technologies
    Inventors: Oleg Melnyk, Nathalie Ollivier, Reda Mhidia, Julien Dheur
  • Patent number: 10028945
    Abstract: A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: July 24, 2018
    Assignee: Signature Therapeutics, Inc.
    Inventors: Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
  • Patent number: 9982014
    Abstract: The present invention is to provide a method for the efficient production on an industrial scale of SS-31 (D-Arg-Dmt-Lys-Phe-NH2), which is an SS peptide. According to the present invention, the desired SS-31 is produced by efficiently synthesizing a tetrapeptide compound as a precursor of SS-31 and improving the tetrapeptide purity by crystallization.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: May 29, 2018
    Assignees: Kaneka Corporation, Stealth BioTherapeutics Corp
    Inventors: Yoshinori Hirai, Akira Nishiyama, Masaru Mitsuda
  • Patent number: 9951099
    Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein the peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting the peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized ?-helical structure; and (2) contacting the crosslinked stabilized ?-helical structure with MDM2.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 24, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Christian E. Schafmeister
  • Patent number: 9902754
    Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analog comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analog thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof, wherein an amino-terminal residue of the peptide is N-alkylated.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: February 27, 2018
    Assignee: University of Copenhagen
    Inventors: Anders Bach, Kristian Stromgaard
  • Patent number: 9803262
    Abstract: Provided are an extraction agent and extraction method that selectively extract and, at a low cost, recover gallium from an acidic solution containing gallium and zinc. The gallium extraction agent comprises an amide derivative represented by general formula (I). In the formula, R1 and R2 each indicate the same or different alkyl group, R3 indicates a hydrogen atom or an alkyl group, and R4 indicates a hydrogen atom or any given group, other than an amino group, bonded to the ?-carbon as an amino acid. The general formula preferably has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. By extracting gallium from an acidic solution containing gallium and zinc by means of solvent extraction using the extraction agent, it is possible to selectively extract gallium.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: October 31, 2017
    Assignees: Kyushu University, National University Corporation, SUMITOMO METAL MINING CO., LTD.
    Inventors: Masahiro Goto, Fukiko Kubota, Yuzo Baba
  • Patent number: 9801951
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 31, 2017
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Patent number: 9629921
    Abstract: The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAP? and the like. These“pro-inhibitors” are activated, i.e., cleaved, by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease can be the same (such as pro-inhibitors being referred to as “Target-Activated Smart Protease Inhibitors” or “TASPI”) or different (e.g., “Target-Directed Smart Protease Inhibitors” or “TDSPI”). After activation of the pro-inhibitor, the active inhibitor moiety can self-inactivate by, e.g., intramolecular-cyclization or cis-trans isomerization.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: April 25, 2017
    Assignee: Trustees of Tufts College
    Inventor: William W. Bachovchin
  • Patent number: 9629893
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: April 25, 2017
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev
  • Patent number: 9522944
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: December 20, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais
  • Patent number: 9464141
    Abstract: The invention provides anti-ETBR antibodies and immunoconjugates and methods of using the same. In some embodiments, an immunoconjugate comprising an antibody that binds ETBR covalently attached to a cytotoxic agent is provided, wherein the antibody binds an epitope within amino acids 64 to 101 of SEQ ID NO: 10. In some embodiments, the cytotoxic agent is a pyrrolobenzodiazepine.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: October 11, 2016
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Suzanna Clark, Paul Polakis
  • Patent number: 9463251
    Abstract: The invention provides anti-ETBR antibodies and immunoconjugates and methods of using the same. In some embodiments, an immunoconjugate comprising an antibody that binds ETBR covalently attached to a cytotoxic agent is provided, wherein the antibody binds an epitope within amino acids 64 to 101 of SEQ ID NO: 10. In some embodiments, the cytotoxic agent is a nemorubicin derivative.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: October 11, 2016
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Suzanna Clark, Paul Polakis
  • Patent number: 9447143
    Abstract: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: September 20, 2016
    Assignee: HELIX BIOMEDIX INC.
    Inventors: Scott M. Harris, Timothy J. Falla, Lijuan Zhang
  • Patent number: 9346850
    Abstract: The present invention is related to a method of producing a peptide, characterized in contacting a reaction mixture with a base after a condensation reaction to hydrolyze while a basic condition is maintained until a ratio of a remaining unreacted active ester of an acid component is decreased to 1% or less in a liquid phase peptide synthesis method. According to the invention, a target peptide of high purity can be simply and efficiently produced by a continuous liquid phase synthesis method. Further, the present invention is related to a method of producing a peptide, characterized in using an amide-type solvent immiscible with water in a liquid phase peptide synthesis method. According to the invention, various peptides can be produced by the liquid phase synthesis method without being restricted by the amino acid sequence of the target peptide.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 24, 2016
    Assignee: KANEKA CORPORATION
    Inventors: Hiroshi Murao, Ken-ichiro Morio, Masaru Mitsuda
  • Patent number: 9334305
    Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: May 10, 2016
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
  • Patent number: 9321810
    Abstract: The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-?, IL-1?, IL-6, MMP-1 and MMP-3.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: April 26, 2016
    Assignee: Cara Therapeutics, Inc.
    Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo
  • Patent number: 9273094
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: March 1, 2016
    Assignee: INSTITUT PASTEUR
    Inventor: Catherine Rougeot
  • Patent number: 9220711
    Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: December 29, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
  • Patent number: 9175041
    Abstract: The present invention relates to the crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline. The present invention also relates to processes for preparing dolamethylleuine and dolaphenvaline. The present invention further relates to computer readable medium with crystal structural data and/or information stored thereon.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: November 3, 2015
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University
    Inventors: George R. Pettit, Thomas Smith, Jun-Ping Xu, Delbert Herald
  • Patent number: 9102708
    Abstract: The present invention relates to methods for forming dicarba bridges in organic compounds. This involves the use of a pair of complementary metathesisable groups on the organic compound, and subjecting the compound to cross-metathesis under microwave radiation conditions. In an alternative, the compounds contain a turn-inducing group between the pair of cross-metathesisable groups to facilitate the cross-metathesis.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: August 11, 2015
    Assignee: SYNGENE LIMITED
    Inventors: Andrea Jane Robinson, William Roy Jackson, Jim Patel, Jomana Elaridi
  • Publication number: 20150148298
    Abstract: The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures.
    Type: Application
    Filed: February 5, 2015
    Publication date: May 28, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Hans-Georg LERCHEN, Sherif El Sheikh, Beatrix Stelet-Ludwig, Sven Golfier, Joachim Schuhmacher, Jean Mark Gnoth, Ursula Krenz
  • Publication number: 20150148523
    Abstract: The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained ?-substituted-?-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected ?-amino acid residues, which are essential for systematic conformational studies of ?-peptide foldamers. New methods are also provided to prepare other ?-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as ?/?-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 28, 2015
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Samuel Helmer Gellman, Li Guo, Michael Giuliano
  • Publication number: 20150148285
    Abstract: The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.
    Type: Application
    Filed: May 8, 2014
    Publication date: May 28, 2015
    Applicant: National Tsing Hua University
    Inventors: Jya-Wei Cheng, Hui-Yuan Yu, His-Tsung Cheng
  • Publication number: 20150141345
    Abstract: This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 21, 2015
    Inventors: Illana Gozes, Saar Oz, Jacqueline Woang Cheing Tiong
  • Publication number: 20150141347
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Patent number: 9035025
    Abstract: A method of producing a molecularly-imprinted material comprises synthesizing a peptide, oligosaccharide or oligonucleotide on a disposable surface modified support to produce a support surface-attached peptide, oligosaccharide or oligonucleotide, providing a selected monomer mixture, contacting the monomer mixture with the support surface-attached peptide, oligosaccharide or oligonucleotide, initiating polymerisation or at least one crosslinking reaction, dissolving or degrading the support surface-attached peptide, oligosaccharide or oligonucleotide and support, and obtaining molecularly imprinted material.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: May 19, 2015
    Assignee: MIP Technologies AB
    Inventors: Börje Sellergren, Maria Magdalena Titirici, Andrew J. Hall
  • Publication number: 20150133368
    Abstract: Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.
    Type: Application
    Filed: May 2, 2013
    Publication date: May 14, 2015
    Inventors: Kyeong-Ok Chang, Yunjeong Kim, William C. Groutas
  • Patent number: 9029503
    Abstract: The invention mainly relates to a method for manufacturing a polypeptide of formula: X1—X?—X2??(III) X1 and X2 each representing a peptide fragment, and X? representing an amino acid residue comprising a thiol function, said method comprising at least one step of ligation reaction between a polypeptide of formula: X1—N(CH2CH2SH)2??(I) and a polypeptide of formula: H—X?—X2.??(II) The invention also relates to the polypeptides of formula (I) themselves and the method for obtaining them, as well as resin supports suitable for obtaining them.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: May 12, 2015
    Assignees: Centre National de la Recherche Scientifique, Institut Pasteur de Lille
    Inventors: Oleg Melnyk, Reda Mhidia, Julien Dheur, Nathalie Ollivier
  • Patent number: 9029505
    Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 12, 2015
    Assignee: Phasebio Pharmaceuticals, Inc.
    Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
  • Publication number: 20150126457
    Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Inventors: Dennis J. Goebel, John Marshall
  • Patent number: 9023957
    Abstract: The present invention generally relates to processes and methods of peptide and protein synthesis. The present invention also relates to specific compounds for use in such processes and methods. It is shown herein that peptides with a C-terminal tertiary N,N-bis(2-mercaptoethyl)-amide (BMEA) undergo N-to-S acyl transfer at weakly acidic pH to form a transient thioester which can be captured for direct ligation with a cysteinyl peptide. These C-terminal BMEA peptides are easily prepared with standard Fmoc solid-phase synthesis protocols, thus giving a very convenient access to the thioester components for native chemical ligation.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 5, 2015
    Assignee: Nanyang Technological University
    Inventor: Chuan Fa Liu
  • Patent number: 9023988
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. Macrocycles of the invention include triazole moieties that crosslink amino acid side chains. The cross links can stabilize a secondary structure of a peptidomimetic macrocycle, such as an ?-helix.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 5, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Publication number: 20150119552
    Abstract: Disclosed herein are compositions and methods related to aromatic-cationic peptides. In particular, the compositions and methods relate to aromatic-cationic peptides in conjunction with cytochrome c. In some embodiments, the aromatic-cationic peptide comprises one or more of D-Arg-Tyr-Lys-Phe-NH2 (P-231), DArg-D-Dmt-D-Lys-D-Phe-NH2, and D-Arg-D-Tyr-D-Lys-D-Phe-N H2 (P-2310). In some embodiments, the method relates to increasing cytochrome c reduction, enhancing electron diffusion through cytochrome c, enhancing electron capacity in cytochrome c, and/or inducing novel n-n interactions around cytochrome c.
    Type: Application
    Filed: April 11, 2013
    Publication date: April 30, 2015
    Inventor: D. Travis Wilson
  • Publication number: 20150119330
    Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Patrick A. McGee, Kenneth W. Jackson, Victoria J. Christiansen
  • Publication number: 20150121569
    Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.
    Type: Application
    Filed: July 1, 2014
    Publication date: April 30, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNITERSITE PAUL SABATIER TOULOUSE III
    Inventors: Jean-Philippe COMBIER, Dominique LAURESSERGUES, Guillaume BECARD, Francois PAYRE, Serge PLAZA, Jerome CAVAILLE, Jerome CAVAILLE
  • Publication number: 20150119334
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 30, 2015
    Applicant: Ben-Gurion niversity of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Publication number: 20150119341
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Wei Yang, Yi-Qun Shi
  • Publication number: 20150119342
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: February 20, 2012
    Publication date: April 30, 2015
    Applicants: Universita' Degli Studi Di Milano, Fondazione Cariplo, CISI Scrl, Fondazione IRCCS Istituto Nazionale dei Tumori
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • Patent number: 9018169
    Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: April 28, 2015
    Assignee: Duke University
    Inventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
  • Publication number: 20150111837
    Abstract: The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: A-Thr-Lys-Pro-B-C-D-X, where: A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gin, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg, Thr-Lys-Pro-Arg-Gly.
    Type: Application
    Filed: May 28, 2013
    Publication date: April 23, 2015
    Applicant: "IVIX" Ltd.
    Inventors: Nikolay Fedorovich Myasoedov, Lyudmila Alexandrovna Andreeva, Dmitriy Viktorovich Golikov
  • Patent number: 9011816
    Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: April 21, 2015
    Assignee: Case Western Reserve University
    Inventors: Zheng-Rong Lu, Xueming Wu
  • Patent number: 9011919
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 21, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, David L. Lewis, Darren H. Wakefield, Torsten Hoffmann, Eric Kitas, Peter Mohr, Philipp Hadwiger, Wilma Thuer, Linda Valis
  • Publication number: 20150104458
    Abstract: A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.
    Type: Application
    Filed: August 26, 2014
    Publication date: April 16, 2015
    Applicant: Biomay AG
    Inventors: Rudolf VALENTA, Margit Weghofer, Susanne Vrtala, Friedrich Horak, Peter Valent, Stefan Florian
  • Publication number: 20150105535
    Abstract: Methods of making copolymers are described.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Claire Coleman, John Schaeck, Alicia Thompson